Exosome Diagnostics Significantly Expands Access and Coverage for its EPI Prostate Cancer Test through Agreement with FedMed
February 01, 2018 07:35 ET
|
Exosome Diagnostics
Waltham, MA, Feb. 01, 2018 (GLOBE NEWSWIRE) -- Exosome Diagnostics, Inc., announced today that it has executed an agreement to provide its prostate cancer risk assessment test, ExoDx®...
Exosome Diagnostics Executes Agreement with America’s Choice Provider Network Expanding Access and Coverage for EPI to 28 Million Member Network in the US
January 25, 2018 07:30 ET
|
Exosome Diagnostics
Waltham, MA, Jan. 25, 2018 (GLOBE NEWSWIRE) -- Exosome Diagnostics, Inc., today announced that it has entered into a preferred provider network agreement with America’s Choice Provider Network...
HIFU for Prostate Cancer Now Available at Chesapeake Urology
January 23, 2018 10:00 ET
|
HIFU Prostate Services
CHARLOTTE, N.C., Jan. 23, 2018 (GLOBE NEWSWIRE) -- HIFU Prostate Services, LLC, the leading provider of HIFU technology to physician practices in the United States, is excited to announce a...
OTraces’ TME Cancer Blood Test Presentation at Innovation Challenge Spurs Investor Interest from JP Morgan Healthcare Conference Participants
January 11, 2018 13:39 ET
|
OTraces, Inc.
SAN FRANCISCO and BALTIMORE, Jan. 11, 2018 (GLOBE NEWSWIRE) -- OTraces Inc., a Sykesville, Maryland-based cancer diagnostics company with a unique patented and patent-pending blood test which...
Exosome Diagnostics Announces Positive Coverage for EPI from Largest Payor in the Mid-Atlantic Region
January 08, 2018 13:15 ET
|
Exosome Diagnostics
Waltham, MA, Jan. 08, 2018 (GLOBE NEWSWIRE) -- Exosome Diagnostics announced today that the largest private payor in the Mid-Atlantic region has reached a positive coverage decision for its...
Exosome Diagnostics Launches National Sales Team to Support Flagship Test, ExoDx®Prostate(IntelliScore)
January 03, 2018 07:30 ET
|
Exosome Diagnostics
Waltham, MA, Jan. 03, 2018 (GLOBE NEWSWIRE) -- Expounding upon the very successful regional introduction of the ExoDx Prostate(IntelliScore), or EPI, Exosome Diagnostics is thrilled to announce...
Exosome Diagnostics Executes Coverage Agreement for its EPI Test with Three Rivers Provider Network
December 04, 2017 07:33 ET
|
Exosome Diagnostics
Boston, MA, Dec. 04, 2017 (GLOBE NEWSWIRE) -- Exosome Diagnostics, Inc. announced today that it has executed an agreement for coverage of its prostate cancer risk assessment test, ExoDx®...
Exosome Diagnostics Announces National Medicare Reimbursement Rate Set at $760 for its Prostate Cancer IntelliScore Test
November 27, 2017 08:16 ET
|
Exosome Diagnostics
Boston, MA, Nov. 27, 2017 (GLOBE NEWSWIRE) -- Exosome Diagnostics, Inc. announced today that the national Medicare price for its prostate cancer risk assessment test, ExoDx® Prostate(IntelliScore),...
Telix Pharmaceuticals and ANMI Partner for Prostate Cancer Imaging
October 23, 2017 19:00 ET
|
Telix Pharmaceuticals Limited
MELBOURNE, Australia and LIÈGE, Belgium, Oct. 24, 2017 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (Telix, Company), a clinical-stage biopharmaceutical company focused on the development...
HIFU for Prostate Cancer now Available at North Carolina Specialty Hospital in Durham, North Carolina
September 13, 2017 12:54 ET
|
HIFU Prostate Services
CHARLOTTE, N.C., Sept. 13, 2017 (GLOBE NEWSWIRE) -- HIFU Prostate Services, LLC, the leading provider of HIFU technology to physician practices in the United States, has partnered with North...